{"id":1556,"date":"2005-12-31T00:00:40","date_gmt":"2005-12-30T17:00:40","guid":{"rendered":"https:\/\/www.hivnat.org\/dev\/?p=1556"},"modified":"2005-12-31T00:00:40","modified_gmt":"2005-12-30T17:00:40","slug":"publications-in-2005","status":"publish","type":"post","link":"https:\/\/www.hivnat.org\/en\/publications\/1556\/","title":{"rendered":"Publications 2005"},"content":{"rendered":"\n\t\t\t\t\n
  1. Duncombe C, Kerr SJ, Ruxrungtham K, Dore GJ, Law MG, Emery S, Lange JM, Phanuphak P, Cooper DA. HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting<\/strong>.AIDS.<\/a> 2005 Jan 28;19(2):169-78. <\/li>
  2. Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, Phanuphak P, Ruxrungtham K, Lange J, Cooper DA. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs<\/strong>. AIDS.<\/a> 2005 Jan 28;19(2):185-92.<\/li>
  3. Lolekha R, Sirivichayakul S, Siangphoe U, Pancharoen C, Kaewchana S, Apateerapong W, Mahanontharit A, Chotpitayasunondh T, Ruxrungtham K, Phanuphak P, Ananworanich J. Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A\/E<\/strong>.Clin Infect Dis.<\/a> 2005 Jan 15;40(2):309-12. Epub 2004 Dec 21. <\/li>
  4. Pace C, Emanuel EJ, Chuenyam T, Duncombe C, Bebchuk JD, Wendler D, Tavel JA, McNay LA, Phanuphak P, Forster HP, Grady C. The quality of informed consent in a clinical research study in Thailand<\/strong>. IRB.<\/a> 2005 Jan-Feb;27(1):9-17. <\/li>
  5. Ananworanich J. HIV in Children<\/strong>. The Thai Red Cross Society Magazine (Thai). Jan to Mar 2005. <\/li>
  6. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection<\/strong>. Clin Infect Dis.<\/a> 2005 Feb 15;40(4):594-600. Epub 2005 Jan 26.<\/li>
  7. Ananworanich J, Hirschel B. Interrupting highly active antiretroviral therapy in patients with HIV<\/strong>. Expert Rev Anti Infect Ther.<\/a> 2005 Feb;3(1):51-60. <\/li>
  8. Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment<\/strong>.Clin Infect Dis.<\/a> 2005 Mar 1;40(5):728-34. Epub 2005 Feb 4. <\/li>
  9. Fagard C, Bandelier CY, Ananworanich J, Le Braz M, G\u00fcnthard H, Perneger T, Garc\u00eda F, Hirschel B; Staccato\/SSITT Study Group. Biphasic decline of CD4 cell count during scheduled treatment interruptions. <\/strong>AIDS.<\/a> 2005 Mar 4;19(4):439-41. <\/li>
  10. Ananworanich J, Chantaphakul H, Teeratakulpisarn S, Siangphoe U, Ubolyam S, Chuenyam T, Ungsedhaphan C, Lange J, Cooper D, Phanuphak P, Ruxrungtham K. No effect of interleukin-2 on IgE levels given in addition to antiretroviral therapy in HIV-infected adults with CD4 >300 cells\/mm3<\/strong>. Asian Pac J Allergy Immunol.<\/a> 2005 Mar;23(1):23-8. <\/li>
  11. Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P. The 48-week efficacy of once-daily saquinavir\/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy<\/strong>.HIV Med.<\/a> 2005 Mar;6(2):122-8. <\/li>
  12. Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study<\/strong>. J Acquir Immune Defic Syndr.<\/a> 2005 Aug 15;39(5):523-9. <\/li>
  13. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, Prasithsirikul W, Sankote J, Mahanontharit A, Ruxrungtham K. Efavirenz levels and 24 – week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin<\/strong>. AIDS.<\/a> 2005 Sep 23;19(14):1481-6. <\/li>
  14. Sabik L, Pace CA, Forster-Gertner HP, Wendler D, Bebchuk JD, Tavel JA, McNay LA, Killen J, Emanuel EJ, Grady C. Informed consent: practices and views of investigators in a multinational clinical trial<\/strong>. IRB.<\/a> 2005 Sep-Oct;27(5):13-8. <\/li>
  15. Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, Engchanil C, Ruxrungtham K, Burger D; HIV-NAT 017 Study Team. Pharmacokinetics and 24-week efficacy\/safety of dual boosted saquinavir\/lopinavir\/ritonavir in nucleoside-pretreated children<\/strong>. Pediatr Infect Dis J.<\/a> 2005 Oct;24(10):874-9. <\/li>
  16. Autar RS, Boffito M, Hassink E, Wit FW, Ananworanich J, Siangphoe U, Pozniak A, Cooper DA, Phanuphak P, Lange JM, Ruxrungtham K, Burger DM. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients<\/strong>. J Antimicrob Chemother.<\/a> 2005 Nov;56(5):908-13. Epub 2005 Oct 4. <\/li>
  17. Boyd MA, Siangphoe U, Ruxrungtham K, Duncombe CJ, Stek M, Lange JM, Cooper DA, Phanuphak P. Indinavir\/ritonavir 800\/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009<\/strong>. HIV Med.<\/a> 2005 Nov;6(6):410-20. <\/li>
  18. Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B; Staccato Study Group. A prospective study of efficacy and safety of once-daily saquinavir\/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients<\/strong>. Antivir Ther.<\/a> 2005;10(6):761-7. <\/li>
  19. Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, Sangkote J, Bunyaprawit P, Horsakulchai M, Lange J, Cooper D, Phanuphak P, Ruxrungtham K. Pharmacokinetics of reduced-dose indinavir\/ritonavir 400\/100 mg twice daily in HIV-1-infected Thai patients<\/strong>. Antivir Ther.<\/a> 2005;10(2):301-7. <\/li>
  20. Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, Sujaikaew K, Cooper DA, Lange JM, Phanuphak P, Ruxrungtham K, Burger DM. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis<\/strong>. Antivir Ther.<\/a> 2005;10(8):937-43. <\/li>
  21. Ananworanich J. Immununizations for persons infected with human immunodeficienty virus<\/strong>. Textbook on vaccines and vaccines preventable infectious diseases (Thai) by the Pediatric Infectious Disease Society of Thailand. 2005:331-343.<\/li>
  22. Pancharoen C, Ananworanich J, Thisyakorn U. Preventive Strategies of Perinatal HIV-1 Transmission: An Experience from Thailand<\/strong>. Sociedad Iberoamericana de Informaci\u00f3n Cient\u00edfica (SIIC) 2005: 13(3): 10-13.<\/li>
  23. Guillemin GJ1<\/sup>, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex<\/strong>.Neurotox Res.<\/a> 2005;7(1-2):103-23. <\/li><\/ol>\n\t\t","protected":false},"excerpt":{"rendered":"

    Duncombe C, Kerr SJ, Ruxrungtham K, Dore GJ, Law MG, Emery S, Lange JM, Phanuphak P, Cooper DA. HIV disease progression in a patient cohort treated via a clinical research… <\/p>\n","protected":false},"author":1,"featured_media":1743,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[],"class_list":["post-1556","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publications"],"_links":{"self":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/1556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/comments?post=1556"}],"version-history":[{"count":0,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/1556\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/media\/1743"}],"wp:attachment":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/media?parent=1556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/categories?post=1556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/tags?post=1556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}